Dr Zakharia on Real-World Outcomes With First-Line Axitinib Plus Pembrolizumab in RCC

Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.

Related Keywords

Yousef Zakharia ,University Of Iowa Hospitals ,International Metastatic ,University Of Iowa ,Database Consortium ,Iowa Hospitals ,International Kidney Cancer Symposium ,Onclive Tv ,Genitourinary Cancer ,